Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.44 |
| ▸ | GRM5 | P41594 | 9/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.43 |
| ▸ | CPT1A | P50416 | 5/20 | 0.42 |
| ▸ | CPT2 | P23786 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797292 | 1.00 | HCRTR1 (0.44) | HCRTR1GRM5HCRTR2CPT1ACPT2 | |
| SCHEMBL795246 | 0.90 | CPT1A (0.44) | CPT1ACPT2 | |
| SCHEMBL15480824 | 0.90 | HCRTR1 (0.43) | HCRTR1GRM5HCRTR2CPT1ACPT2 | |
| SCHEMBL795892 | 0.90 | CPT1A (0.44) | CPT1ACPT2 | |
| SCHEMBL808242 | 0.90 | HCRTR1 (0.43) | HCRTR1GRM5HCRTR2CPT1ACPT2 | |
| SCHEMBL795517 | 0.88 | HCRTR1 (0.44) | HCRTR1HCRTR2CPT1ACPT2 | |
| SCHEMBL17220084 | 0.83 | HSD11B1 (0.46) | GRM5 | |
| SCHEMBL17219958 | 0.83 | HSD11B1 (0.41) | GRM5 | |
| SCHEMBL795958 | 0.81 | DPP4 (0.44) | HCRTR1HCRTR2CPT1ACPT2 | |
| SCHEMBL794710 | 0.81 | DPP4 (0.44) | HCRTR1HCRTR2CPT1ACPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | HCRTR1 537/4885GRM5 67/4885HCRTR2 204/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | HCRTR1 537/4885GRM5 67/4885HCRTR2 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.